FDA requires NAION warning on GLP-1 drug labels
|
The facts
- The FDA requires all GLP-1 drugs to add labeling about a potential increased risk of NAION.
- The warning applies to Ozempic, Wegovy, Mounjaro and Zepbound.
- NAION results from reduced blood flow to the optic nerve.
- NAION can cause sudden vision loss, including permanent vision loss in some cases.
- NAION cases have been reported with all currently marketed GLP-1 products.
- The FDA says a causal relationship between GLP-1 drugs and NAION has not been established.
Context
What is NAION?
Nonarteritic anterior ischemic optic neuropathy, or NAION, is an optic-nerve condition caused by reduced blood flow that can lead to sudden, painless vision loss, sometimes permanently. NBC News Hill Aol
Where Left and Right agree
Left and right largely agree on this one.
- What both sides accept
- Patients on any GLP-1 drug should know about the NAION vision-loss risk now labeled, even though causation remains unproven.
- Where Left and Right differ in emphasis
- The left and the right agree on the new warning but part over whether uncertainty should favor caution or patient choice.
How left and right read it
Patients should not carry uncertainty alone. That is why labeling across Ozempic, Wegovy, Mounjaro and Zepbound matters: NAION cases have been reported with every marketed GLP-1, and reduced blood flow to the optic nerve can cause sudden, sometimes permanent vision loss. Causation isn't established, yet why should that gap set the default rather than the eyesight of the people taking these drugs?
Labeling across Ozempic, Wegovy, Mounjaro and Zepbound does exactly that, because NAION has been reported with every marketed GLP-1, and reduced blood flow to the optic nerve can take sight suddenly, sometimes permanently. Causation is not established, so the label informs rather than decides — keep watch on your own vision, because that judgment stays yours.
“You're going to want to keep an eye on this.” — New York Post
Causation remains unproven, so the fight becomes about defaults: whether uncertainty should favor caution or patient judgment.
The receipts — 100 sources
Wire services (8)
Other coverage (92)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.